Pharma Mar (OTCMKTS:PHMMF – Get Free Report) saw a significant drop in short interest in August. As of August 14th, there was short interest totaling 94 shares, a drop of 52.8% from the July 30th total of 199 shares. Based on an average daily volume of 27 shares, the days-to-cover ratio is currently 3.5 days. Approximately 0.0% of the company’s stock are short sold.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on PHMMF shares. Zacks Research raised Pharma Mar to a “hold” rating in a research report on Monday, June 15th. Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Pharma Mar has a consensus rating of “Buy”.
Check Out Our Latest Stock Analysis on PHMMF
Pharma Mar Stock Performance
About Pharma Mar
PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.
The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.
Recommended Stories
- Five stocks we like better than Pharma Mar
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
- OneMain’s Yield Comes With a Catch
- 3 AI Infrastructure Stocks to Watch Beyond NVIDIA
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.
